AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), today announced data from the final analysis of its Phase 2 randomized discontinuation trial evaluating tivozanib, its lead product candidate designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors, in patients with advanced renal cell carcinoma (RCC). Data showed that the median progression-free survival (PFS) achieved among all patients (both clear cell and non-clear histologies) treated with tivozanib was 11.7 months and, as previously presented, 14.8 months among those with clear cell RCC who had undergone nephrectomy, which is the same patient population being evaluated in AVEO’s ongoing Phase 3 trial comparing tivozanib to sorafenib (Nexavar®), called TIVO-1. Additionally, Phase 1 data evaluating tivozanib in combination with the mTOR inhibitor temsirolimus (Torisel®) in patients with RCC demonstrated tolerability and tumor shrinkage. These data are being presented in two poster discussion sessions at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), abstracts number 4550 and 4549, respectively.
